Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.9K
Overview
51.9K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.0K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.6K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.6K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

655
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
655
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.1K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Immunogens Designed by AI Epitope Prioritization Confer Protection Against <i>Mycobacterium tuberculosis</i>.

Vaccines·2026
Same author

Perspectives on the Development of Immune Memory Associated with Vaccination.

Vaccines·2026
Same author

Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection.

Vaccines·2026
Same author

Latent tuberculosis infection in high TB disease burden countries dysregulates cellular and immunological profiles which is further enhanced with uncontrolled hyperglycemia.

Scientific reports·2026
Same author

Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome.

Journal of translational medicine·2025
Same author

Innate immune molecular landscape following controlled human influenza virus infection.

Cell reports·2025

Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K

Tuberculosis vaccines: Opportunities and challenges.

Bingdong Zhu1, Hazel M Dockrell2, Tom H M Ottenhoff3

  • 1Lanzhou Center for Tuberculosis Research and Institute of Pathogen Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

Respirology (Carlton, Vic.)
|January 18, 2018
PubMed
Summary

Developing new tuberculosis (TB) vaccines is crucial as the current BCG vaccine shows variable efficacy in adults. Research is exploring novel vaccine candidates and identifying immune markers to improve protection against TB.

Keywords:
biomarkersclinical trialsimmunitytuberculosisvaccines

More Related Videos

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

649

Related Experiment Videos

Last Updated: Feb 15, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K
Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence
10:06

Imaging Mycobacterium tuberculosis in Mice with Reporter Enzyme Fluorescence

Published on: February 26, 2018

7.8K
Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis
08:48

Separation and Fractionation of Culture Filtrate Proteins (CFPs) from Mycobacterium tuberculosis

Published on: July 11, 2025

649

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a significant global health challenge.
  • Bacillus Calmette-Guérin (BCG) is the sole licensed TB vaccine, effective in children but with variable efficacy in adults.
  • There is an urgent need for improved TB vaccines, especially for adult populations.

Purpose of the Study:

  • To review current and emerging novel tuberculosis vaccine candidates.
  • To discuss the challenges in identifying correlates of vaccine-induced protection against TB.
  • To highlight the importance of new biomarkers for future TB vaccine development.

Main Methods:

  • Review of existing literature on TB vaccines in clinical trials.
  • Analysis of novel vaccine platforms including whole-cell, subunit, viral vector, DNA, and RNA-based vaccines.
  • Examination of immunological assays and biomarkers for assessing vaccine immunogenicity and efficacy.

Main Results:

  • At least 12 novel TB vaccine candidates are in clinical trials, employing diverse strategies like recombinant BCG, killed mycobacteria, protein subunits, and viral vectors.
  • Cell-mediated immune responses, such as interferon-gamma (IFN-γ) production, are used to assess immunogenicity, but correlates of protection are not yet established.
  • Emerging evidence suggests central memory T cells and local secreted IgA may correlate with protection against TB disease.

Conclusions:

  • Identifying reliable correlates of protection is essential for the success of clinical TB vaccine efficacy trials.
  • Future TB vaccine design requires a deeper understanding of Mycobacterium tuberculosis antigens and immune profiles associated with protection or disease risk.
  • Investment in biomarker research is critical for developing next-generation TB vaccines with improved and consistent efficacy.